What type of study is this?

December 8, 2025Blood

Long-acting GM-CSF-based drug conjugate effectively targets leukemia stem cells in Acute Myeloid Leukemia with limited toxicity

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis shows GM-DM1 improves cytotoxicity in Acute Myeloid Leukemia, suggesting its potential targeting of leukemia stem cells.

GM-DM1 induced significant apoptosis selectively in leukemia stem cells while sparing normal hematopoietic cells, showcasing its targeted action.
Pharmacokinetics of GM-DM1 revealed a 50-fold increase in serum half-life compared to native GM-CSF, enhancing its therapeutic window.
Humanized mouse model confirmed minimal myeloid suppression and preservation of bone marrow architecture after GM-DM1 treatment, indicating a favorable safety profile.
This innovative use of GM-CSF receptor targeting may provide a novel approach to reduce relapse in Acute Myeloid Leukemia patients.

Xiao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows GM-DM1 improves cytotoxicity in Acute Myeloid Leukemia, suggesting its potential targeting of leukemia stem cells.